RAPP

Neutral

Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock

Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, sold 20,225 shares of company stock for $808,844 on April 17, 2026, through ...

Investing.com 1 week ago 0

Neutral

How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026

Rapport Therapeutics (RAPP) will present new 8-week follow-up data from its Phase 2a trial of RAP-219 for focal onset seizures at the 2026 American Ac...

Simply Wall Street 2 weeks ago 0